BR1019 not checked
Boryung Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects take the investigational products once a day for 12 weeks.”In the company’s words, NCT06220773 on ClinicalTrials.gov
- Tested for
- Essential Hypertension, Type 2 Diabetes Mellitus
- Main trialPhase 3
- “The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus”In the company’s words, NCT06220773 on ClinicalTrials.gov
Other drugs for Essential Hypertension
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227AAddpharma Inc. · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
- BR1400-1Boryung Pharmaceutical Co., Ltd · Phase 2
Coming up1
- DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2026 | A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | |
| Phase 1Completed | 31 Mar 2024 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" | |
| Phase 1Completed | 11 Dec 2024 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026